Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Rebecca Yanhui Zhang-Roper"'
Autor:
Marinella Della Negra, Srinivas Rao Valluri, Carlo Giaquinto, Kulkanya Chokephaibulkit, Manoli Vourvahis, Ismail Mitha, Andrew Clark, Jan Fourie, Jayvant Heera, Charles Craig, Rebecca Yanhui Zhang-Roper, Lynn McFadyen, Elna van der Ryst, Muthuhadini Patience Mawela, Annie Fang
Publikováno v:
The Pediatric Infectious Disease Journal
Supplemental Digital Content is available in the text.
Background: Maraviroc is a CC-chemokine receptor 5 antagonist approved to treat adults infected with CC-chemokine receptor 5–tropic (R5) HIV-1. Study A4001031 was conducted to evaluate the
Background: Maraviroc is a CC-chemokine receptor 5 antagonist approved to treat adults infected with CC-chemokine receptor 5–tropic (R5) HIV-1. Study A4001031 was conducted to evaluate the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f80069e97e7c0f7c3305dba6fd350d3
https://pubmed.ncbi.nlm.nih.gov/29023357
https://pubmed.ncbi.nlm.nih.gov/29023357
Autor:
Jayvant Heera, Gerd Fätkenheuer, Juergen K. Rockstroh, Rebecca Yanhui Zhang-Roper, David M. Asmuth, Juan A. Pineda, Catherine B. Small, Meena B. Bansal, Frank Plonski, Ronnie Wang, Gilles Pialoux
Publikováno v:
Antiviral therapy, vol 22, iss 3
Rockstroh, JK; Plonski, F; Bansal, M; Fätkenheuer, G; Small, CB; Asmuth, DM; et al.(2017). Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial. Antiviral Therapy, 22(3), 263-269. doi: 10.3851/IMP3116. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/68s6t2xj
Rockstroh, JK; Plonski, F; Bansal, M; Fätkenheuer, G; Small, CB; Asmuth, DM; et al.(2017). Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial. Antiviral Therapy, 22(3), 263-269. doi: 10.3851/IMP3116. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/68s6t2xj
Background In the primary 48-week analysis of a hepatic safety trial in patients with HIV-1 coinfected with HBV and/or HCV, maraviroc-containing treatment regimens were not associated with increased hepatotoxicity. Methods In this randomized, double-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc9105ca039483e32d0dd9d068b5bfb8
https://escholarship.org/uc/item/68s6t2xj
https://escholarship.org/uc/item/68s6t2xj
